Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. - sprookjes - yvandenbroek - TriplyDB

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

http://www.wikidata.org/entity/Q36835070

about

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment Elotuzumab for the treatment of multiple myeloma The Role of Immunotherapy in Multiple Myeloma Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Targeted therapy for HM1.24 (CD317) on multiple myeloma cells Development of Novel Immunotherapies for Multiple Myeloma Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors The role of SLAMF7 in multiple myeloma: impact on therapy.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Novel immunotherapies The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era New strategies in the treatment of multiple myeloma.Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways Targeting cell surface β2 -microglobulin by pentameric IgM antibodies GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.Antibody-based therapies in multiple myeloma Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.Profile of elotuzumab and its potential in the treatment of multiple myeloma The development of potential antibody-based therapies for myeloma Progress in myeloma stem cells Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.Haematological malignancies: at the forefront of immunotherapeutic innovation.

P2860

Q26738944-A8E477CE-0CA4-449C-836B-E93BA5524D2D Q26740278-00BA6C2F-6531-445F-90D6-98A9FF367FBA Q26771144-9BB62CFB-4D95-4C08-A93A-2F7223677B16 Q26799104-64481C62-1A8F-4B26-A8E1-0E806341CF2A Q26822754-BC2835AC-2294-4C9E-8925-12F0AD6AE372 Q27026161-6AE6F34B-5EE6-484A-A709-406769B6DC3E Q28066890-CCD21F30-FC6D-4686-813B-84BB4D88F940 Q28075816-292FC3D7-CC45-45FF-BACF-A621173B14E9 Q28076147-6D51AC2F-7C9D-4775-B3B1-C6191DC92329 Q28078993-305E8463-6CA7-4065-A3C0-2B4B77817D1A Q28115588-258B8516-9215-44F4-A53B-249521485497 Q28291155-62890B28-C8A6-4524-9227-10A8FC041057 Q28537997-A2A4269A-6E8F-40E5-9F2E-7478A82C7507 Q30249167-228195F4-0BA5-4335-AFBA-50F474C981EB Q30249513-535E4B3E-6FAC-468D-96F5-D1B1B641A0C9 Q30275870-B6AC43C5-17EA-4D45-9745-16BDFB7406FF Q33402671-0667B5E1-E3F5-41FE-AC32-6BEE6B277B90 Q33621610-043E6CA4-0B7B-4455-94DE-0836AC6F21D4 Q33822677-6E5C60F6-7E9B-4082-A17F-0A06CBDFA83C Q33840201-E795AA20-CAFF-4323-B262-50E6B485180D Q33909086-23E1479B-FB41-4E7A-AC5B-2295C6B676F0 Q33958520-4F3A9923-D45D-46D4-9583-3CCA8136609B Q33992425-CD2D2F36-8CF3-4A8D-955D-1A441F93B09B Q34420112-7D729393-717A-4F02-B8F6-36DD33AFBC4A Q34502870-DFE60184-B333-4911-AA49-D308F423E134 Q34634446-823C3944-DA53-497A-80B6-42D05A9FBD44 Q34635516-6BD911B1-2822-4454-9C91-36FC507FE41D Q34718149-184FEDEB-CD26-4E88-82DA-5CEFDCA4535E Q34773850-FE4A4513-BE9C-479B-9D9A-B3F7F0223A7F Q34807860-909DF508-83C4-466A-A423-2CF66EC8A0C4 Q35036633-B902C0E9-DB0D-41FF-96AD-18C386E9B767 Q35146307-45C06FCA-905B-4C36-BD0A-B41730F4294B Q35431150-0B6B39D8-CB4F-4744-8205-2EDC4F844EA2 Q35514038-3A837987-2CD2-474B-8F66-31B122A67F1A Q35610286-7B5E9CA6-AF4F-4773-BDD0-E154D9247DD3 Q35628678-88A89E2F-42C0-4DDB-BEAD-F52BB1F97A01 Q35788245-2916A741-B0EE-4538-99E4-7A19B370260A Q35824980-7C77D858-27CB-46B4-BDDD-87008C81B6C4 Q35832168-FB525470-866F-40C6-A824-FB7B735ED9C5 Q35880618-5FA9130E-9857-4235-9369-B2F758863A20

P2860

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

http://www.wikidata.org/entity/Q36835070

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Anti-CS1 humanized monoclonal ...... ity in the bone marrow milieu.

@en

type

label

Anti-CS1 humanized monoclonal ...... ity in the bone marrow milieu.

@en

prefLabel

Anti-CS1 humanized monoclonal ...... ity in the bone marrow milieu.

@en

P1433

Q36835070-6AE2163B-66D5-4603-AF10-28DB58DB5664

P1476

Q36835070-2B8D5FA6-3B63-403B-B3D0-8C1326880C97

P2093

Q36835070-15254685-6AC3-4690-AE93-79D73D05CD99

Q36835070-2D281761-D60F-454E-B5BA-D229F1886234

Q36835070-31CC329E-655D-4A00-BF92-BE928FC2A070

Q36835070-41843D50-BDDE-440E-99D7-358780D64072

Q36835070-43889F4E-4CED-4F5E-BC1F-A76936C1EAD4

Q36835070-454974D4-66C8-4AFF-8FAA-DBDB05CBB55B

Q36835070-463FB0AB-8C7B-43A4-AEEC-955E9515CF86

Q36835070-465D2125-3970-49CB-B9A3-456211A0B3EA

Q36835070-79FB932D-B842-4C25-BE92-65814EF4F08D

Q36835070-7A16587F-CA12-46B0-BED7-A9556BE1BDDC

P2860

Q36835070-01ECF1B1-B44E-43E1-815D-BFC2F450546B

Q36835070-136715CF-8F56-4C4E-9FA5-9EB2355270A4

Q36835070-1BB976EA-2375-4D1D-A5E3-FCF9604082A8

Q36835070-34152401-B840-41B1-AE3A-1128FBA0F619

Q36835070-3663BE90-8A04-45CD-88EB-AFA6122FB66A

Q36835070-384A0CF0-8BBC-4E47-A4B4-969008869C28

Q36835070-5EC67F72-A1C4-447D-B1FC-8F7E7834A052

Q36835070-670844C3-A82B-45B0-93C7-B44F4D12D700

Q36835070-6EF6FE5A-5347-4FF6-963D-43448D1E83A6

Q36835070-74F8145F-FDF5-4AC9-8241-A8342698876D

P304

Q36835070-914717E9-BB7D-4497-93C8-FAF07EA663FD

P31

Q36835070-A7E4A653-AA2D-4E57-99ED-9D004DEDBA5C

P356

Q36835070-80B6B0ED-ED42-495C-B0E4-CA4D64D6E132

P407

Q36835070-6A39F075-EF1C-4A38-ADBE-30293FC77382

P433

Q36835070-1B1092CC-EE8F-4721-995C-CD8E6B403E39

P478

Q36835070-9209C261-A823-4718-B14E-6FEB1DC66702

P50

Q36835070-2A17E213-41B9-414E-BB3B-327671472134

Q36835070-7A780BBD-8075-4C29-A53D-10C33DB2FFD3

Q36835070-BE4B0CBE-C2F4-4DBE-9D29-C3938BB99C0B

P577

Q36835070-A4F5F6E5-03C3-41AD-B0F5-8CEB571AD054

P5875

Q36835070-B5C6C386-78E1-40CB-A037-F8F88745913F

P698

Q36835070-112662FF-51E4-422B-9AD9-729070CE561D

P921

Q36835070-1A8E3690-E435-44A3-BF9D-B8C52A0A2573

Q36835070-88908677-8221-4730-BC75-4AEDBB8EB7B8

P932

Q36835070-04380DD9-1A13-4697-B957-4C47FC8F0E24

P356

BLOOD-2007-08-107292

P1433

P1476

Anti-CS1 humanized monoclonal ...... ity in the bone marrow milieu.

@en

P2093

Alfred I Lee

http://www.w3.org/2001/XMLSchema#string

Anne van Abbema

http://www.w3.org/2001/XMLSchema#string

Audie G Rice

http://www.w3.org/2001/XMLSchema#string

Claire Mathiot

http://www.w3.org/2001/XMLSchema#string

Daniel E H Afar

http://www.w3.org/2001/XMLSchema#string

Debbie Law

http://www.w3.org/2001/XMLSchema#string

Edie Weller

http://www.w3.org/2001/XMLSchema#string

Ingrid Caras

http://www.w3.org/2001/XMLSchema#string

Klaus Podar

http://www.w3.org/2001/XMLSchema#string

Lynne Jesaitis

http://www.w3.org/2001/XMLSchema#string

P2860

A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion

CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function

A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen

2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes

Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.

2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.

P304

1329-1337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-08-107292

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Hervé Avet-Loiseau

Kenneth C Anderson

Paul G Richardson

P577

2007-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5939028

http://www.w3.org/2001/XMLSchema#string

P698

17906076

http://www.w3.org/2001/XMLSchema#string

P921

P932

2515112

http://www.w3.org/2001/XMLSchema#string